All In Biotech

Drug Trial Radar · NCT06030193

Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)

A Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Aug 13, 2025

Primary completion

Feb 23, 2026

Study completion Mar 23, 2026

Sponsor

Lead sponsor
Qlaris Bio, Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.

Conditions

  • Normal Tension Glaucoma (NTG)
  • Low-Tension Glaucoma, Bilateral
  • Low-Tension Glaucoma, Unspecified Eye
  • Glaucoma

Interventions

  • QLS-111 ophthalmic solution (0.015%)Drug

    QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

  • Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)Drug

    Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)Time frame: 14 days
  2. Clinically significant change in visual acuityTime frame: 14 days
  3. Clinically significant change in findings on slit lamp examTime frame: 14 days
  4. Clinically significant change in findings on fundus examTime frame: 14 days
  5. Incidence of systemic TEAEsTime frame: 14 days
  6. Clinically significant changes in blood pressure (BP)Time frame: 14 days
  7. Clinically significant changes in heart rate (HR)Time frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.